

EASL SCHOOL OF HEPATOLOGY

PERSONALISED MEDICINE IN HEPATOBILIARY MALIGNANCIES

Faculty:

University Hospital Heidelberg, Heidelberg, Germany:

- Pathology and Molecular Pathology:
- Prof. Peter Schirmacher, Prof. Albrecht Stenzinger, Prof. Thomas Longerich
- Hepatology: Dr. Dr. Michael Dill
- Oncology: Prof. C. Springfeld

Hannover Medical School, Hannover, Germany:

- GI-Oncology: PD Dr. Anna Saborowski

Hannover Medical School, Hannover, Germany and University of Toronto, Toronto, Canada:

- GI-Oncology: Prof. Arndt Vogel

Trinity College Dublin, Dublin, Ireland:

- GI-Oncology: Prof. Grainne O’Kane

DAY 1 – Friday 26 April 2024

08:30-09:00	Arrival and Registration	
09:00-09:30	Welcome Housekeeping, introduction to materials, aim, and format of the school and of the presenters	
09:30-10:00	What does individualized medicine mean? Introductory pitch and discussion	A. Saborowski, P. Schirmacher
Session 1: Molecular diagnostics		
10:00-11:00	Key diagnostic technologies and assays (Exoms, Panels, DNA and RNAseq, Liquid and Tissue) <i>Presentation with discussion</i>	A. Stenziger
11:00-11:30	Coffee break	
11:30-12:30	Parallel break-out workshop (flipped classroom with experts): Group work: Discussion of cases contributed by delegates	Faculty: all
12:30-13:00	Where will molecular diagnostics be in 5 years? Innovation in the context of technologies, regulations and clinical need <i>Discussion with pitch</i>	C. Springfield, A. Vogel, P. Schirmacher
13:00-14:00	Lunch	
Session 2: Individualized treatment strategies		
14:00-14:45	Treatment strategies and molecular targets in biliary cancers <i>Presentation</i>	G. O’Kane
14:45-15:30	Treatment strategies and therapeutic sequencing in hepatocellular carcinoma <i>Presentation</i>	A. Saborowski
15:30-16:00	Molecular tumor board: reality and needs <i>Presentation</i>	C. Springfield
16:00-16:30	“Beyond state-of-the-art”: Integrating early clinical evidence and real-world data in decision making in hepatobiliary cancers <i>Presentation</i>	M. Dill
16:30-16:45	Coffee break	
16:45-18:15	Parallel break-out workshop (flipped classroom) with coffee Group work: What’s known and what’s next: genomic targets in hepatobiliary cancers - 5 groups (max. 5 delegates/group) - Preparation of slides to be presented in the final session (topics allocated prior to event)	Faculty: all
Evening	Social event	

DAY 2 – Saturday 27 April 2024

Session 3: Perspectives

08:30-09:00	What has to be considered? From data protection and IVDR to companion diagnostics - Regulations that frame personalized medicine <i>Presentation</i>	P. Schirmacher
09:00-09:30	Resistance testing, pharmacogenomics and liquid biopsy: concepts and challenges when navigating individual patient journeys in molecularly guided therapy <i>Presentation</i>	A. Vogel
09:30-10:30	Parallel break-out workshop (flipped classroom): Morphology meets molecularly based therapy: live microscopy session - Group 1: Morpho-molecular features of hepatobiliary cancers that matter for therapy – the basics (dedicated to delegates who are not pathologists) - Group 2: Solving diagnostic challenges in hepatobiliary malignancies (dedicated to delegates who are pathologists)	P. Schirmacher, T. Longerich
10:30-11:00	The current gaps, challenges and opportunities in hepatobiliary cancers <i>Presentation</i>	A. Vogel
11:00-11:15	Coffee break	
Session 4: Group presentation, wrap up, and conclusion		
11:15-12:45	Workshop (flipped classroom): Presentation of results from “ What’s known and what’s next: genomic targets in hepatobiliary cancers ” group work - 10 min presentation + 5 min discussion	
12.45-13:15	What to expect from hepatobiliary cancer therapy in 5 years? From targets to trials and translation <i>Concluding discussion</i>	Faculty: all
13:15-13:30	Closure and farewell Wrap up, prize for best presentation, follow-up and feedback session	
13:30	Take-away lunch	

